January 28, 2021 10:55 PM ESTUpdated 08:13 AM
R&D

J&J push­es new ami­van­tam­ab da­ta for NSCLC sub­set, try­ing to bol­ster case for quick FDA ap­proval

Max Gelman

Senior Editor

Hav­ing al­ready filed for a quick OK for ami­van­tam­ab in a sub­set of metasta­t­ic non-small cell lung can­cer pa­tients, J&J’s Janssen unit on Thurs­day pre­sent­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times